Hormone Therapy vs. Non-Hormonal Support for Menopause

Menopausal hormone therapy uses estrogen — with a progestogen when clinically needed — to treat certain menopause symptoms, primarily hot flashes, night sweats, and genitourinary symptoms. Non-hormonal support is a much broader category: prescription medications, behavioral therapies, lifestyle approaches, local vaginal treatments, and dietary supplements, with evidence strength that varies considerably from one option to the next. These aren't opposing camps — many women use some combination of both, and the right approach depends on your specific symptoms, health history, and goals.

Hormone Therapy vs. Non-Hormonal Support at a Glance

No option here is "best" in the abstract — evidence strength is symptom- and context-specific, which the table below breaks down further.

This isn't actually a binary choice

"Hormone therapy vs. non-hormonal support" is a useful comparison for understanding your options, but real-world menopause care is rarely an either/or decision. A woman might use hormone therapy for hot flashes and CBT-I for sleep. She might use a non-hormonal medication instead of hormone therapy due to a personal risk factor, while also adjusting lifestyle habits. She might use local vaginal estrogen for genitourinary symptoms while choosing not to pursue systemic hormone therapy at all. None of these combinations are unusual, and none require picking a single "team." This article exists to help you understand the actual landscape of options — not to sort you into one camp.

What menopausal hormone therapy actually is

Menopausal hormone therapy (MHT), sometimes still called hormone replacement therapy (HRT), involves taking estrogen — alone, or combined with a progestogen — to address symptoms related to declining ovarian hormone production. It's available in multiple forms: oral tablets, transdermal patches, gels, sprays, and vaginal rings for systemic delivery, plus separate low-dose vaginal formulations for local, non-systemic use.

Why uterus status matters: women with an intact uterus who use systemic estrogen generally need a progestogen alongside it, because estrogen alone can cause the uterine lining to thicken over time, increasing endometrial cancer risk. Women without a uterus (following a hysterectomy) typically don't need a progestogen and may use estrogen alone. This distinction is a core part of why hormone therapy isn't "one drug" — it's a category with meaningfully different formulations depending on individual anatomy and history.

What hormone therapy is best supported for

The Menopause Society describes hormone therapy as the most effective treatment available for bothersome vasomotor symptoms — hot flashes and night sweats — in appropriate candidates. It's also FDA-approved, in certain formulations, for prevention of bone loss, and effectively addresses genitourinary symptoms related to declining estrogen. It is not a universal treatment for every menopause-related concern, and claiming otherwise oversimplifies what the evidence actually supports.

Brain fog: hormone therapy is not established as a reliable treatment for cognitive complaints, and it is not shown to prevent dementia — claims to the contrary oversimplify a genuinely complex, still-evolving area of research. (See [Brain Fog and Hormone Change →] for what actually helps with this specific symptom.)

Mood: research suggests estradiol, particularly transdermal formulations, may help with mood symptoms specifically tied to the perimenopausal hormonal window for some women — this is different from using hormone therapy as a general treatment for major depressive disorder, which has its own separate, established treatment pathway. (See [Mood, Anxiety, Irritability, and Hormonal Transition →].)

Weight: hormone therapy is not shown to cause weight loss, and shouldn't be positioned as a body-composition treatment. Changes in fat distribution around menopause reflect a combination of aging, hormonal shifts, and lifestyle factors — not something hormone therapy is designed or proven to reverse.

Who might be a good candidate

Candidacy for hormone therapy is genuinely individualized — this isn't a self-screening checklist, and we're not going to pretend it is one. These are factors clinicians typically consider together, not separately: age and how many years since menopause onset, symptom burden, whether you have a uterus, personal and family history of cardiovascular disease or blood clots, cancer history (particularly hormone-sensitive cancers), liver disease, any unexplained vaginal bleeding, and your own preferences and goals. The honest answer to "am I a candidate" is a conversation with a provider who knows your full history, not a list you check off yourself.

Timing matters — the current evidence, precisely stated

Current guidance draws a real distinction based on age and time since menopause. Randomized evidence supports reduced all-cause mortality and fracture risk when hormone therapy is initiated within approximately 10 years of menopause onset — generally before age 60 — in appropriate candidates. This is often referred to as a "window of opportunity" in the research literature. This doesn't mean hormone therapy is automatically unsafe after that window, or automatically safe within it — individual health history still matters more than age alone. It means the benefit-risk balance shifts meaningfully with timing, which is worth understanding rather than oversimplifying into "safe under 60."

Hormone therapy risks, in context — not as one number

This is the area where the most outdated information still circulates, so precision matters. As of November 2025 and February 2026, the FDA began removing boxed-warning language related to cardiovascular disease, breast cancer, and probable dementia from menopausal hormone therapy products, following a comprehensive review of evidence generated since the original Women's Health Initiative trials — evidence that reflected an older, on-average less symptomatic study population than typically initiates hormone therapy today. This does not mean hormone therapy carries no risk. The endometrial cancer risk associated with unopposed estrogen in women with a uterus remains a genuine, unremoved warning — progestogen use in this population isn't optional, it's protective.

Risk also isn't uniform across formulations: estrogen-alone therapy and estrogen-plus-progestogen therapy have different risk profiles; oral and transdermal routes have different clotting-risk profiles (more below); and individual factors — personal and family history, age, timing, dose, duration — all meaningfully shape actual risk for any individual woman. A single number can't responsibly summarize this, which is exactly why individualized conversation with a provider matters more than a generic "HRT is risky" or "HRT is safe" headline either way.

Does the route of administration matter?

Yes, meaningfully, particularly for clotting risk. Oral estrogen passes through the liver first, which increases production of clotting proteins; transdermal estrogen (patches, gels, sprays) bypasses this first-pass metabolism. Multiple studies, including large real-world analyses, have found lower venous thromboembolism risk with transdermal estrogen compared to oral. Current NICE guidance specifically recommends transdermal therapy for women at elevated VTE risk, including those with a BMI over 30. Neither route shows a clear advantage for breast cancer risk or bone health. This isn't a case of one route being universally superior — it's a genuine, evidence-based factor to discuss with your provider given your individual risk profile.

What "non-hormonal" actually means — and what it doesn't

This is one of the most commonly misunderstood terms in menopause care. "Non-hormonal" is not one treatment category with one evidence level — it spans everything from FDA-approved prescription pharmaceuticals to unregulated supplements, and treating those as equivalent does a disservice to accurate understanding.

FDA-approved non-hormonal medications for vasomotor symptoms. As of 2026, this category includes fezolinetant (Veozah, approved 2023, carries a liver-monitoring boxed warning added in 2024), elinzanetant (Lynkuet, approved October 2025, dual-receptor mechanism, also shows sleep benefit), and low-dose paroxetine (Brisdelle, approved 2013, the only antidepressant specifically FDA-approved for VMS). These are real pharmaceuticals with real clinical trial data behind them — not "natural alternatives," and worth understanding as their own distinct, evidence-backed category.

Other prescription options, used off-label. SSRIs and SNRIs beyond low-dose paroxetine, gabapentin, and oxybutynin all have guideline-supported evidence for hot flashes even though they weren't developed or FDA-approved specifically for that purpose. This off-label-but-evidence-supported distinction matters: it doesn't mean weaker evidence, just a different regulatory pathway than a drug developed specifically for VMS.

Behavioral interventions. Cognitive behavioral therapy (CBT) and clinical hypnosis have real evidence behind them — not for changing estrogen deficiency itself, but for meaningfully changing how bothersome symptoms feel and improving sleep quality specifically. CBT for insomnia (CBT-I) in particular is considered a first-line treatment for menopausal insomnia in the clinical literature, with a randomized trial specifically in perimenopausal and postmenopausal women with vasomotor symptoms supporting its effectiveness. This is a genuinely different category from generic "manage your stress" advice — it's a structured, evidence-based clinical intervention.

Lifestyle and general health support. Exercise, consistent sleep habits, smoking cessation, alcohol moderation, and cooling strategies are good general health practices, and some are associated with modest symptom improvement — but it's important not to conflate "healthy habit" with "proven hot-flash treatment." These matter as part of a broader approach, not as a substitute for direct symptom treatment when symptoms are significant.

Dietary supplements and botanicals. Major menopause guidelines do not currently recommend dietary supplements as vasomotor symptom treatments, largely because the overall evidence across the category is inconsistent — different extracts, doses, and study populations make it hard to draw firm conclusions. That said, this doesn't mean supplements are unscientific across the board: some nutrients have well-established physiological roles, and certain standardized botanical extracts do have real human clinical research behind them for specific outcomes. Evidence genuinely varies by ingredient, and lumping them all together — either dismissing all of them or overselling all of them — misrepresents the actual evidence landscape. (See [Supplements for Menopause: Strong, Mixed, and Limited Evidence →] for an ingredient-by-ingredient breakdown.)

Local vaginal therapies and GSM: a genuinely different category

Genitourinary syndrome of menopause (GSM) — vaginal dryness, discomfort during sex, and related urinary symptoms tied to declining estrogen in these tissues — has its own distinct treatment landscape that doesn't map cleanly onto the "hormone therapy vs. non-hormonal" framing used elsewhere in this article.

Non-hormonal options include vaginal moisturizers and lubricants, which can meaningfully help with dryness and comfort without any hormonal component.

Low-dose vaginal estrogen is technically hormonal, but delivers minimal systemic absorption — current evidence, including a large study of postmenopausal women with a prior stroke, has not found increased VTE, stroke, or cancer risk with this local formulation, which is why current FDA labeling review has specifically moved to differentiate it from systemic hormone therapy risk.

Vaginal DHEA (prasterone) is another local option, converted to estrogen and androgen within vaginal tissue itself, with minimal systemic absorption.

Ospemifene is an oral, non-estrogen medication (a selective estrogen receptor modulator) FDA-approved specifically for painful sex related to GSM — genuinely non-hormonal in mechanism despite acting on estrogen receptors in vaginal tissue.

The key point: don't let "hormonal vs. non-hormonal" as a general framework obscure how different local GSM treatment actually is, risk-wise, from systemic hormone therapy — they shouldn't be grouped together when discussing risk.

Which options have evidence for which symptoms?

Important caveat: this table reflects evidence strength for each category broadly. Individual medications, ingredients, and interventions within each column vary — this is a starting framework for conversation, not a substitute for the detail found in symptom-specific articles linked throughout this piece.

Cancer history and hormone therapy

This requires real nuance, and we're not going to reduce it to a blanket statement in either direction. Whether hormone therapy is appropriate after a cancer diagnosis depends on cancer type, hormone-receptor status, treatment history, individual recurrence risk, current symptoms, and whether local versus systemic treatment is being considered. Non-hormonal options — including fezolinetant and elinzanetant, given their non-hormonal mechanism — are increasingly used specifically for hot flashes in breast cancer survivors, including those on anti-estrogen therapy, and research specifically studying this population continues to grow. Women with a cancer history genuinely benefit from coordinated guidance between their oncology team and a menopause specialist, rather than a general practitioner working from generic guidance alone.

Surgical menopause and risk-reducing surgery

Treatment discussions often look different when both ovaries are removed before natural menopause, because hormone loss happens abruptly and often at a younger age than natural menopause — this includes both medically necessary surgery and risk-reducing surgery for BRCA1/BRCA2 mutation carriers. Whether hormone therapy is appropriate still depends on individual factors: age at surgery, personal cancer history, uterus status, and other risk factors. This isn't a population where a universal recommendation applies evenly — it's one where individualized guidance matters even more given the abruptness and often-younger age involved. (Full discussion: [Surgical Menopause: What Changes Overnight →].)

"Non-hormonal" doesn't mean "no medication" — and it's worth saying plainly

A common misconception worth correcting directly: non-hormonal treatment is very often real, evidence-based prescription medication — not simply "the natural option" or "the supplement option." Fezolinetant, elinzanetant, low-dose paroxetine, gabapentin, and oxybutynin are all pharmaceuticals with clinical trial data behind them. "Non-hormonal" describes a mechanism, not a level of rigor, regulation, or effectiveness.

And "natural" doesn't automatically mean safer

Supplements aren't inherently risk-free simply because they're not hormones. They can interact with medications, affect liver enzyme function, interact with blood thinners, vary in actual composition between products, and create unintended duplicate nutrient exposure when combined with other supplements or a multivitamin. This isn't meant to create fear about supplements broadly — it's meant to establish that safety depends on the specific intervention and how it's used, not on whether a label says "natural."

Can you use hormone therapy and non-hormonal support together?

Often, yes, depending on the specific interventions and your individual clinical picture. Common combinations include hormone therapy alongside CBT-I for sleep, hormone therapy alongside lifestyle changes, hormone therapy paired with foundational nutritional support, local vaginal treatment used alongside a decision not to pursue systemic therapy, or a non-hormonal prescription medication combined with behavioral treatment. This isn't unusual, and it reinforces the core point of this whole article: this isn't a binary choice, and the right combination is worth building with your provider based on your specific symptoms and goals — not assembled from a generic list.

Questions worth bringing to your provider

• Given my specific symptoms and history, is hormone therapy a reasonable option for me?
• If hormone therapy isn't right for me, which non-hormonal prescription options have the strongest evidence for what I'm experiencing?
• Should I be considering oral or transdermal estrogen, and why?
• Do I need a progestogen, given my uterus status?
• How does my personal or family history affect my risk profile specifically?
• What would you recommend if I want to explore lifestyle or nutritional support alongside whatever we decide on treatment?
• If I have a cancer history, should this conversation include my oncology team?

(For the full appointment-prep framework: [Questions to Ask Your Doctor About Perimenopause and Menopause →].)

Where foundational non-hormonal support fits

Her Reclaim CORE is a non-hormonal daily dietary supplement designed to support foundational functions — including energy, mood, cognitive function, healthy stress response, metabolic health, and overall wellness. CORE is not intended to diagnose, treat, cure, or prevent menopause or any disease. It is designed as foundational nutritional and botanical support and can sit alongside individualized medical care where appropriate — it's not a replacement for hormone therapy, not an alternative to HRT, and not a substitute for the prescription or behavioral options discussed throughout this article when those are what's clinically indicated. If you're using hormone therapy or any prescription medication, review any new supplement with your provider or pharmacist rather than assuming compatibility.

Frequently asked questions

What is menopausal hormone therapy? Treatment using estrogen — alone or combined with a progestogen — to address menopause symptoms like hot flashes, night sweats, and genitourinary symptoms, available in oral, transdermal, and local vaginal forms.

What is the difference between HRT and non-hormonal menopause treatment? Hormone therapy uses estrogen (with progestogen when needed); non-hormonal support is a broad category including FDA-approved prescription medications, behavioral therapies, lifestyle approaches, and supplements — with widely varying evidence strength.

Is hormone therapy the most effective treatment for hot flashes? Yes, according to The Menopause Society, hormone therapy is the most effective treatment for bothersome vasomotor symptoms in appropriate candidates — though it isn't the only effective option, and isn't right for every woman.

What are FDA-approved non-hormonal medications for hot flashes? As of 2026: fezolinetant (Veozah), elinzanetant (Lynkuet), and low-dose paroxetine (Brisdelle) — all real pharmaceuticals, not supplements.

Is fezolinetant a hormone? No. It's a neurokinin-3 receptor antagonist that works on brain pathways involved in temperature regulation, not on estrogen or progesterone levels.

Can antidepressants help hot flashes? Yes — low-dose paroxetine is specifically FDA-approved for this. Other SSRIs and SNRIs have guideline-supported evidence for hot flashes when used off-label.

Are supplements an alternative to HRT? No — major guidelines don't recommend supplements as a treatment for vasomotor symptoms due to inconsistent overall evidence, though individual ingredients vary and some have real, if limited, research behind them for specific outcomes.

Can you take supplements while using hormone therapy? Sometimes, but not automatically — some supplements can interact with hormone metabolism or other medications. Review any supplement with your provider or pharmacist rather than assuming compatibility.

Is transdermal estrogen safer than oral estrogen? For blood clot risk specifically, current evidence suggests transdermal estrogen carries lower risk than oral, and NICE guidance recommends it for women at elevated VTE risk. Neither route shows a clear advantage for breast cancer risk or bone health.

Does hormone therapy help sleep? It can, particularly when sleep disruption is driven by hot flashes and night sweats — improving the underlying vasomotor symptoms often improves sleep as a result.

Does hormone therapy help brain fog? It's not established as a reliable treatment for cognitive complaints, and it doesn't prevent dementia — this is a common oversimplification worth correcting directly.

Does hormone therapy cause weight gain? No — hormone therapy is not shown to cause weight gain, nor is it shown to cause weight loss. Body composition changes around menopause reflect a combination of factors beyond hormone therapy use.

Who should not use hormone therapy? Candidacy is individualized based on factors including cardiovascular and clotting history, certain cancer histories, liver disease, and unexplained bleeding — this is a conversation for your provider, not a self-determined list.

Can women without a uterus use estrogen without progesterone? Generally yes — progestogen is primarily needed to protect the uterine lining, so women who've had a hysterectomy typically don't require it alongside estrogen therapy.

Can hormone therapy and non-hormonal treatments be used together? Often, yes — many women combine approaches, such as hormone therapy for hot flashes alongside CBT-I for sleep, depending on their specific symptoms and goals.

What are the options if I can't use estrogen? Non-hormonal prescription medications (fezolinetant, elinzanetant, low-dose paroxetine, and off-label options like gabapentin), CBT/behavioral therapy, and lifestyle approaches all remain available and evidence-supported.

Is vaginal estrogen the same as systemic HRT? No — low-dose vaginal estrogen has minimal systemic absorption and a meaningfully different risk profile than systemic hormone therapy, which is why current FDA labeling review treats them differently.

References

Clinical guidelines / position statements

The Menopause Society (formerly NAMS) — 2023 Nonhormone Therapy Position Statement https://menopause.org

NICE Guideline NG23 — Menopause: Diagnosis and Management (2024 update)https://www.ncbi.nlm.nih.gov/books/NBK552590

FDA / regulatory sources

U.S. Food and Drug Administration — FDA Approves Labeling Changes to Menopausal Hormone Therapy Products (February 12, 2026) https://www.fda.gov/news-events/press-announcements/fda-approves-labeling-changes-menopausal-hormone-therapy-products

U.S. Department of Health and Human Services — FDA Initiates Removal of Boxed Warnings from Menopausal Hormone Therapy Products (November 10, 2025) https://www.hhs.gov/press-room

U.S. Food and Drug Administration — FDA Adds Warning About Rare Occurrence of Serious Liver Injury with Use of Veozah (Fezolinetant) (December 16, 2024) https://www.fda.gov

Systematic reviews / comparative evidence

Comparative Evidence Between Transdermal and Oral Menopausal Hormone Therapy — NCBI Bookshelf (Canadian Drug Agency rapid review) https://www.ncbi.nlm.nih.gov/books/NBK614933

Hormonal Therapies and Venous Thrombosis: Considerations for Prevention and Management, PMChttps://pmc.ncbi.nlm.nih.gov/articles/PMC9399360

Primary research

McCurry SM, et al. — Telephone-Based Cognitive Behavioral Therapy for Insomnia in Perimenopausal and Postmenopausal Women With Vasomotor Symptoms: A MsFLASH Randomized Clinical Trial, JAMA Internal Medicine, 2016

Epic Research — Blood Clot Risk Influenced by Hormone Therapy Administration Route in Women 50 and Older (2025) https://www.epicresearch.org

Authoritative patient education

Harvard Health Publishing — FDA Removes Menopause Hormone Therapy Black Box Warningshttps://www.health.harvard.edu/womens-health/fda-removes-menopause-hormone-therapy-black-box-warnings

Related Her Reclaim guides

• What Is Perimenopause?
• What Is Menopause?
• The Hormone Change Guide
• Surgical Menopause: What Changes Overnight
• Brain Fog and Hormone Change
• Mood, Anxiety, Irritability, and Hormonal Transition
• Sleep, Night Sweats, and Fatigue During Menopause
• Supplements for Menopause: Strong, Mixed, and Limited Evidence
• Questions to Ask Your Doctor About Perimenopause and Menopause

There's no single right answer here — only the answer that's right for your body, your history, and what you're actually trying to solve. Your hormones changed. You didn't, and neither does your right to real, current information about your options.